STOCK TITAN

Zynex Medical to Participate in H.C. Wainwright Annual Global Investment Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

ENGLEWOOD, Colo. , Sept. 1, 2022 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the Company's management will participate virtually in the H.C. Wainwright Annual Global Investment Conference. Interested parties can access the webcast on the Events section of the website at https://zynexmed.investorroom.com/ir-home on Monday, September 12th, 2022, at 7am ET.

About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com 

Investor Contact
Gilmartin Group
650 Fifth Ave., Suite 2720
New York, NY 10019
IR@zynex.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/zynex-medical-to-participate-in-hc-wainwright-annual-global-investment-conference-301616246.html

SOURCE Zynex

Zynex Inc

NASDAQ:ZYXI

ZYXI Rankings

ZYXI Latest News

ZYXI Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Medical Specialties, Health Technology, Manufacturing, Surgical and Medical Instrument Manufacturing

About ZYXI

zynex, inc. founded in 1996, engineers, manufactures and markets neuro-diagnostics, stroke rehabilitation, pain management and cardiac monitoring devices within three subsidiaries. zynex medical is a provider of electrotherapy products for home use. zynex monitoring solutions develops products for cardiac monitoring for use in hospitals. zynex neurodiagnostics develops devices for emg and eeg diagnostic applications within neurology disciplines. zynex medical's product line is fully developed, fda/ce cleared, commercially sold, and has been developed to uphold the company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. zynex monitoring solutions and zynex neurodiagnostics are currently both in the development stages without any significant revenues.